Primary pulmonary hypertension

被引:9
作者
Stuart Rich
机构
[1] Rush Medical College,
[2] Rush-Presbyterian-St. Luke’s Medical Center,undefined
关键词
Pulmonary Hypertension; Pulmonary Arterial Hypertension; Prostacyclin; Pulmonary Artery Pressure; Main Side Effect;
D O I
10.1007/s11936-000-0006-1
中图分类号
学科分类号
摘要
引用
收藏
页码:135 / 139
页数:4
相关论文
共 41 条
[1]  
Rubin LJ(1997)Primary pulmonary hypertension N Engl J Med 336 111-117
[2]  
Abenhaim L(1996)Appetite-suppressant drugs and the risk of primary pulmonary hypertension N Engl J Med 335 609-616
[3]  
Moride Y(1997)Mapping of familial primary pulmonary hypertension locus (PPH1) to chromosome 2q31-32 Circulation 95 2603-2606
[4]  
Brenot F(1998)Inhaled nitric oxide in primary pulmonary hypertension: a safe and effective agent for predicting response to nifedipine J Am Coll Cardiol 32 1068-1073
[5]  
Morse JH(1998)Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension N Engl J Med 338 273-277
[6]  
Jones AC(1987)High-dose calcium channelblocking therapy for primary pulmonary hypertension: evidence for long-term reduction in pulmonary arterial pressure and regression of right ventricular hypertrophy Circulation 76 135-141
[7]  
Barst RJ(1992)The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension N Engl J Med 327 76-81
[8]  
Ricciardi MJ(1984)Adverse hemodynamic and clinical effects of calcium channel blockage in pulmonary hypertension secondary to obliterative pulmonary vascular disease J Am Coll Cardiol 4 890-901
[9]  
Knight BP(1996)A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension N Engl J Med 334 296-301
[10]  
Martinez FJ(1997)Primary pulmonary hypertension: improved long-term effects and survival with continuous intravenous epoprostenol infusion J Am Coll Cardiol 30 343-349